Acalabrutinib
Treatment for Chronic Lymphoid Leukemia
Typical Dosage: 100mg twice daily orally
Effectiveness
88%
Safety Score
45%
Clinical Trials
83
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
100mg twice daily orally
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$160,000
Monitoring:$5,000
Side Effect Mgmt:$4,000
Total Annual:$169,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
1.3
Outcome-Based Costs
Cost per Responder
$211,250
Cost per Remission
$1,126,667
Comparison vs Bendamustine + Rituximab
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Acalabrutinib Outcomes
for Chronic Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+80%
Remission Rate
+15%
Common Side Effects
Headache
+39%
Diarrhea
+38%
Bruising
+36%
Neutropenia
+29%
Infections
+25%
Sources:
Active Clinical Trials
13 active trials recruiting for Acalabrutinib in Chronic Lymphoid Leukemia
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT05557695RECRUITING
350 participants
OBSERVATIONAL
Aylesbury, United Kingdom +28 more
Started: Oct 17, 2022
Retention Rate of Acalabrutinib in a Non-interventional Setting
NCT05645172ACTIVE NOT RECRUITING
137 participants
OBSERVATIONAL
D Ren, Germany +60 more
Started: Dec 12, 2022
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Charlotte, United States +22 more
Started: Feb 4, 2025
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696ACTIVE NOT RECRUITINGPHASE3
533 participants
INTERVENTIONAL
Phoenix, United States +130 more
Started: Jul 28, 2015
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611ACTIVE NOT RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Tucson, United States +22 more
Started: Mar 8, 2016
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
NCT05950997RECRUITINGNA
89 participants
INTERVENTIONAL
Nanjin, China
Started: Apr 16, 2024
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273ACTIVE NOT RECRUITINGPHASE1
12 participants
INTERVENTIONAL
Krakow, Poland +10 more
Started: Jan 31, 2018
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
NCT02157324ACTIVE NOT RECRUITINGPHASE1
12 participants
INTERVENTIONAL
Columbus, United States +2 more
Started: Aug 18, 2014
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
NCT07014917RECRUITINGPHASE2
62 participants
INTERVENTIONAL
Cincinnati, United States
Started: Dec 5, 2025
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019RECRUITINGPHASE3
170 participants
INTERVENTIONAL
Tucson, United States +69 more
Started: Aug 5, 2024
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192RECRUITINGPHASE3
202 participants
INTERVENTIONAL
Bad Saarow, Germany +29 more
Started: Apr 19, 2022
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
NCT03580928ACTIVE NOT RECRUITINGPHASE2
72 participants
INTERVENTIONAL
Stamford, United States +3 more
Started: Aug 7, 2018
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
NCT07024706NOT YET RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Started: Sep 30, 2025
Completed Clinical Trials
5 completed trials for Acalabrutinib in Chronic Lymphoid Leukemia
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
NCT04883749COMPLETEDPHASE2
53 participants
INTERVENTIONAL
Innsbruck, Austria +19 more
Started: Jun 1, 2021
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
NCT04008706COMPLETEDPHASE3
552 participants
INTERVENTIONAL
Chandler, United States +107 more
Started: Sep 17, 2019
Acalabrutinib Real World Italian obSErvational Study -ARISE
NCT06205498COMPLETED
151 participants
OBSERVATIONAL
Alessandria, Italy +40 more
Started: Aug 8, 2023
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL
NCT03787264COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Cologne, Germany +16 more
Started: Jan 14, 2019
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
NCT03788291COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Rochester, United States
Started: Mar 25, 2019
Showing 20 of 86 total trials